Reason for request
Extension of indication
Clinical Benefit
| Substantial |
Substantial in the treatment of SJIA. |
Clinical Added Value
| moderate |
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. |
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
HE4S5v3g255YuzjY
